Researchers have uncovered key immune mechanisms behind IgA nephropathy, a major form of chronic kidney disease affecting millions worldwide. Their breakthrough work strongly suggests that the disease ...
Understanding eGFR and uPCR is vital for managing IgA nephropathy to predict kidney health, guide treatment, and work ...
Treatment with atacicept led to a statistically significant 42% reduction in UPCR compared with placebo at week 36. Atacicept, an investigational BAFF (B-cell activating factor)/APRIL (a proliferation ...
Learn how to manage an IgA nephropathy flare with this detailed action plan. Understand symptoms and prevention to safeguard ...
– In a Phase 3 clinical study evaluating the efficacy and safety of sparsentan in Japanese patients with IgA nephropathy (N=35), the percent change from baseline in the 24-hour urine ...
TOKYO, Oct. 10, 2025 /PRNewswire/ -- Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys") announced today that it has completed data collection for the primary endpoint in the Phase III ...